Cladribine

Introduction Overview

Generic Name

cladribine

Brand Name

Mavenclad

Dosage Form

oral tablets

Drug Class

Antimetabolites

Pharmacokinetics

Absorption:
Cladribine is administered orally in tablet form and is well absorbed from the gastrointestinal tract. The oral bioavailability is moderate due to first-pass metabolism and potential degradation in the GI tract. Peak plasma concentrations are typically observed within 0.5 to 2 hours post-dose. Food intake does not significantly affect the absorption, allowing the drug to be administered with or without food, providing flexibility in dosing and patient compliance.

Distribution:
After absorption, cladribine distributes widely into body tissues. It exhibits a large apparent volume of distribution, indicating extensive tissue penetration, including penetration into lymphoid tissues, which is relevant to its immunomodulatory effects. Plasma protein binding is low to moderate, which facilitates distribution into peripheral compartments. Cladribine’s ability to cross cellular membranes allows it to accumulate in cells, especially lymphocytes, which are major targets in multiple sclerosis treatment.

Metabolism:
Cladribine undergoes partial intracellular phosphorylation to its active triphosphate form, which exerts cytotoxic effects by interfering with DNA synthesis and repair. The parent drug is minimally metabolized by hepatic enzymes, reducing the likelihood of extensive hepatic drug interactions. The intracellular activation is critical to its pharmacodynamic effect, and variability in intracellular kinase activity may influence drug efficacy and toxicity.

Elimination:
The elimination half-life of cladribine is approximately 10 to 20 hours, allowing for once-daily dosing during treatment cycles. The drug and its metabolites are primarily excreted via the renal route, with about 60-80% recovered in the urine over 24 hours. Renal clearance contributes significantly to total clearance, and impairment in renal function can impact drug elimination. There is also a minor contribution from biliary excretion. Monitoring renal function is recommended to avoid drug accumulation and toxicity. Cladribine’s long-lasting biological effects reflect its incorporation into DNA, with effects persisting beyond plasma clearance.

Dosage Forms

Available Dosage Forms:
Mavenclad is available as oral tablets containing cladribine in two strengths: 10 mg and 20 mg.

Dosages for Adults and Adolescents:
The dosing regimen involves two annual treatment courses separated by approximately one year. Each treatment course comprises two treatment cycles given one month apart.
- Year 1 treatment: Two cycles; each cycle consists of 4 or 5 consecutive days during which patients take the prescribed oral tablets daily.
- Year 2 treatment: Identical to Year 1, repeated approximately 12 months later.
The total cumulative dose is calculated based on body weight, typically 3.5 mg/kg per year, delivered over the two cycles.

Specific Patient Populations:
- Patients with renal impairment may require dose adjustments or increased monitoring due to altered elimination.
- Use in elderly patients should be cautious due to potential comorbidities and altered clearance.
- Not recommended in pregnant or breastfeeding women.
- Pediatric use is not established.
- Patients with moderate-to-severe liver impairment (Child-Pugh score >6) are contraindicated.
Clinical guidelines stress the importance of frequent lymphocyte counts and infection monitoring due to the immunosuppressive nature of the drug.

Mechanism Of Action

Cladribine, the active component of Mavenclad, is a synthetic purine nucleoside analog that exerts its therapeutic effects primarily through its action as an antimetabolite interfering with DNA synthesis. Once administered, cladribine enters cells via nucleoside transporters and undergoes intracellular phosphorylation by deoxycytidine kinase to form the active metabolite, 2-chlorodeoxyadenosine triphosphate (CdATP).

CdATP accumulates in target lymphocytes and incorporates into the DNA strand, leading to disruption of DNA synthesis and repair processes. This incorporation triggers DNA strand breaks and impairs cellular proliferation, resulting in the selective depletion of pathogenic lymphocytes implicated in the autoimmune pathophysiology of multiple sclerosis. The mechanism preferentially affects dividing and resting lymphocytes, thereby reducing immune-mediated damage within the central nervous system.

Furthermore, cladribine induces apoptosis of T and B lymphocytes through mitochondrial pathways and enhances the clearance of autoreactive immune cells. Its immunomodulatory properties translate clinically into decreased frequency and severity of MS relapses by suppressing aberrant immune responses without inducing broad myelosuppression typical of cytotoxic chemotherapy.

Compared to other disease-modifying therapies, cladribine offers the advantage of short-course oral administration with durable immunological effects beyond the dosing period. Clinical studies demonstrate that its unique selective lymphocyte targeting reduces disease activity and delays disability progression in relapsing-remitting MS. Preclinical and clinical data support the notion that cladribine modulates both cellular and humoral immune pathways, contributing to durable suppression of disease activity.

Pharmacological Actions

Selective immunosuppressant activity targeting lymphocytes.
Purine nucleoside analogue interfering with DNA synthesis and repair.
Induction of apoptosis in T and B lymphocytes.
Reduction of autoreactive immune cell populations implicated in multiple sclerosis.
Immunomodulation resulting in decreased relapse frequency in MS.
Oral administration with durable effects post-treatment.
Minimal myelosuppression compared to traditional chemotherapeutics.
Effective in relapsing-remitting and active secondary progressive forms of MS.
Modulation of cellular and humoral immune responses.
Inhibition of proliferation of pathogenic lymphocytes.
Selective uptake into lymphoid tissues enhancing targeted activity.
Potential antiviral activity via effects on lymphocytes (indirect).
Dose-dependent lymphocyte depletion with gradual immune reconstitution.
Reduction of inflammation and demyelination in CNS.

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis in adults.
Reduction in frequency and severity of MS relapses.
Delay in progression of disability in relapsing-remitting MS.
Treatment option for patients with inadequate response to other disease-modifying therapies.
Management of active secondary progressive multiple sclerosis.
Immunomodulatory therapy targeting autoimmune pathogenesis of MS.
Reduction of central nervous system inflammatory activity evidenced by MRI.
Use as an oral agent providing an alternative to injectable MS therapies.
Treatment for relapsing MS patients aiming for sustained disease control.
Part of therapeutic sequencing in patients failing other immunotherapies.
Potential reduction in corticosteroid requirement due to relapse control.
Improves patient adherence with short duration dosing schedules.
Off-label use in select autoimmune conditions has been investigated.
Adjunct therapy in multi-modal MS treatment strategies.
Use under specialist supervision with close monitoring.

Side Or Adverse Effects

Headache, commonly reported during treatment cycles.
Lymphopenia and decreased white blood cell counts leading to risk of infection.
Upper respiratory tract infections including common cold symptoms.
Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection.
Allergic reactions including hives, facial swelling, and difficulty breathing.
Increased risk of herpes zoster (shingles) infection.
Hepatic toxicity presenting with nausea, vomiting, jaundice, and elevated liver enzymes.
Hematological toxicities such as fever, swollen lymph nodes, mouth sores, and bruising.
Potential increased risk of malignancies, including skin cancers and lymphomas.
Gastrointestinal disturbances including nausea and abdominal pain.
Fatigue and general malaise reported during and after treatment courses.
Hair loss (alopecia) observed infrequently.
Potential for heart failure symptoms such as shortness of breath and swelling.
Injection site reactions are absent due to oral administration, but caution with tablet handling is necessary.
Possible reactivation of latent infections including tuberculosis.

Precautions

Strict contraindication in pregnancy and breastfeeding; use effective contraception during and for 6 months post-treatment.
Screening for active infections including tuberculosis, hepatitis B and C, and HIV before initiation.
Caution in patients with compromised immune systems or prior immunosuppressive therapy.
Liver and kidney function assessment prior to and during treatment due to potential organ toxicity.
Avoid live vaccinations during treatment and for at least 4-6 weeks prior to initiation.
Regular monitoring of lymphocyte counts to guide dosing and prevent severe immunosuppression.
Advise patients on proper handling of tablets to avoid inadvertent exposure.
Patients should avoid close contact with people who have active infections.
Use barrier forms of contraception alongside hormonal methods due to reduced contraceptive efficacy.
Delay dosing or withhold treatment in case of acute infections or significant lymphopenia.
Careful evaluation of cardiac history given potential for heart-related adverse events.
Inform patients about signs of infection, liver injury, and allergic reactions for prompt intervention.
Advise caregivers on precautions in handling bodily fluids due to drug excretion and toxicity.
Close follow-up for at least 2 years after last dose due to persistent pharmacodynamic effects.
Consideration of cancer risk in patients with prior malignancies or risk factors.

Warnings

Boxed warning for increased risk of malignancies and birth defects if used during pregnancy.
Risk of Progressive multifocal leukoencephalopathy (PML), requiring immediate evaluation if neurological symptoms occur.
Severe lymphopenia can predispose to life-threatening infections.
Use contraindicated in patients with active infections including tuberculosis or hepatitis.
Avoid administration during pregnancy; potential teratogenicity affecting male and female germ cells.
Risk of liver injury necessitates monitoring of hepatic function.
Potential reduction in effectiveness of hormonal contraceptives; alternative contraceptives recommended.
Risk of heart failure and related complications must be monitored.
Treatment can induce long-lasting immunosuppression; delay or avoid live vaccines.
Not to be administered with other immunosuppressants or chemotherapy agents without strict medical supervision.
Delayed adverse effects require prolonged follow-up and monitoring.
Do not use in patients with moderate-to-severe liver impairment.
Avoid use in patients with known hypersensitivity to cladribine or excipients.
Risk of reactivation of latent infections including herpes viruses and tuberculosis.
Proper precautions needed in handling to prevent accidental exposure and toxicity.

Contraindication

Pregnancy and breastfeeding.
Known hypersensitivity or allergy to cladribine or related compounds.
Active malignancy or history of cancer within the past 5 years.
Active infections such as tuberculosis, hepatitis B or C, and HIV/AIDS.
Moderate-to-severe hepatic impairment (Child-Pugh score >6).
Immunocompromised patients with ongoing severe infections.
Concurrent treatment with other immunosuppressive or cytotoxic agents unless supervised.
Severe renal impairment may require contraindication or dose adjustment based on clinical judgment.
Patients who have received live vaccines within 4-6 weeks prior to therapy initiation.
Children and adolescents due to lack of established safety and efficacy data.
Known severe cardiac disease may be considered a relative contraindication.
Patients unable to comply with necessary monitoring during treatment.
Patients with active herpes zoster or other herpes virus infections at baseline.
Those unable to use reliable contraception methods during and post-therapy.
Known leukopenia or lymphopenia prior to treatment initiation.

Drug Interactions

Potential interactions with other oral medications taken simultaneously; maintain a 3-hour window before or after Mavenclad administration.
Immunosuppressive agents may potentiate lymphocyte depletion, increasing infection risk.
Live vaccines are contraindicated during and shortly before/after Mavenclad therapy due to immune suppression.
Hormonal contraceptives may have reduced effectiveness; additional barrier contraceptives should be used.
Caution with concomitant hepatotoxic drugs due to additive liver injury risk.
Drugs affecting renal function could alter cladribine elimination and exposure.
Potential additive myelosuppressive effects when combined with chemotherapy or radiation.
Medicinal products altering cytochrome P450 enzymes have minimal effects, as cladribine metabolism is primarily intracellular.
Concurrent antiviral or antibiotic therapies do not show significant pharmacokinetic interaction but require monitoring of infection status.
Agents promoting lymphocyte proliferation may counteract cladribine’s efficacy.
Vaccines given during treatment periods can lead to inadequate immune response or heightened adverse effects.
Avoid concomitant use with other nucleoside analogues to prevent overlapping toxicities.
Interaction potential with herbal supplements is not well studied; disclose all supplements to healthcare provider.
Alcohol use should be minimized due to liver safety considerations.
Monitor closely when switching from or to other disease-modifying therapies for MS.

Preparations Of The Drug

Oral tablets in blister packs: 10 mg and 20 mg strengths.
Each blister pack provides tablets for the prescribed treatment cycles over 4-5 consecutive days per cycle.
Tablets are coated and designed to be swallowed whole; do not crush or chew.
Packaging includes foil blisters to protect from moisture and light.
Detailed patient instruction leaflets accompany each pack, emphasizing safety precautions and handling instructions.
Supplied in quantities aligned with yearly treatment courses.
Proper disposal guidelines included to avoid exposure to broken or crushed tablets.
Storage recommendations specify room temperature, away from excess moisture and heat.
Packaging design considers child-resistant features.
Supplemental materials may include calendars or dosing aids to support adherence.
Availability may vary by region and prescription status is strictly controlled due to toxicity potential.
Commercially distributed under the brand name Mavenclad globally with regulatory approval.
Pharmaceutical formulation ensures stability and bioavailability for optimal therapeutic effect.
Manufactured under Good Manufacturing Practices with batch-specific quality control.
Labeling includes boxed warnings and explicit contraindications as mandated by regulatory agencies.